Venture-capital firm Peppermint VenturePartners GmbH is raising a fund to invest in technologies for patients with vision disorders and heart conditions, The Wall Street Journal reports.
Berlin-based Peppermint seeks up to 100 million euros, equivalent to $118 million, for the cardiology- and ophthalmology-focused fund, according to the firm. In addition to investments in Europe, Peppermint will consider startups in other areas, including the U.S. Read more.
